Centrus Energy (LEU) dropped 26 percent in October 2026, far underperforming the S&P 500's 0.5 percent decline. The stock has now fallen 18.6 percent over two consecutive months, signaling deepening investor concern about management's capital allocation.
The damage began Oct. 19 when Centrus announced its $116 million acquisition of Westerman Holdings—funded with $95 million in cash and $21 million in stock. Shares fell more than 4 percent that day. Investors immediately punished the move, viewing it as a dilutive departure from the company's core nuclear fuel business.
Roth Capital led the rout on Oct. 20, slashing its price target to $115 from $188—a 39 percent cut—while maintaining a neutral rating. Roth cited concerns that Westerman's integration could depress near-term margins and divert management focus from Centrus's high-margin HALEU production. Other analysts quickly followed with downgrades.
Centrus justified the Westerman purchase as a means to build supply-chain resilience and diversify beyond nuclear into oil and gas. That pitch flopped. The market's read: management is overestimating Westerman's synergy potential and underestimating execution risk.
The real story, though, is what the sell-off obscures. Centrus remains the only U.S. producer of high-assay low-enriched uranium (HALEU), the specialized fuel required for small modular reactors (SMRs). As of Sept. 30, the company carried a backlog of $5.4 billion across its low-enriched uranium and HALEU businesses—a substantial moat that hasn't changed.
For long-term investors, the October decline presents a tactical entry point. Westerman integration risk is real but priced in heavily. The structural tailwind—the SMR boom and the U.S. government's commitment to domestic HALEU production—remains intact. Watch Centrus's Q3 2026 earnings for evidence that core nuclear margins hold. If HALEU backlog conversion accelerates despite Westerman noise, the $115 target will look absurdly low.
